Long-term, observational cohort study of adults with plaque psoriasis (PsO), who are new users of deucravacitinib, tumour necrosis factor inhibitor (TNFi) biologics, non-TNFi biologics, or non-biologic therapies in the real-world clinical setting

Study identification

• EU PAS number:
  EUPAS1000000659
• Study ID:
  1000000659
• Official title and acronym:
  Long-term, observational cohort study of adults with plaque psoriasis (PsO), who are new users of deucravacitinib, tumour necrosis factor inhibitor (TNFi) biologics, non-TNFi biologics, or non-biologic therapies in the real-world clinical setting
• DARWIN EU® study:
  No
• Study countries:
  Denmark

  Finland

  France

  Germany

  Norway

  Spain
• Study status:
  Planned

Research institutions and networks

Institutions

Bristol-Myers Squibb (BMS)

Study timelines

Date when funding contract was signed

Actual:06/01/2025

Study start date

Planned:15/12/2025

Date of final study report

Planned:24/12/2032

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Bristol-Myers Squibb

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)